Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Leases (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Current Leases for 5 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 49.87% year-over-year to $3.0 million, compared with a TTM value of $3.0 million through Dec 2025, up 49.87%, and an annual FY2025 reading of $3.0 million, up 49.87% over the prior year.
  • Current Leases was $3.0 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $2.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.5 million in Q1 2023 and bottomed at $2.0 million in Q4 2024.
  • Average Current Leases over 5 years is $2.7 million, with a median of $2.6 million recorded in 2021.
  • The sharpest move saw Current Leases tumbled 34.55% in 2024, then skyrocketed 49.87% in 2025.
  • Year by year, Current Leases stood at $3.4 million in 2021, then fell by 2.37% to $3.3 million in 2022, then tumbled by 31.75% to $2.3 million in 2023, then dropped by 11.54% to $2.0 million in 2024, then skyrocketed by 49.87% to $3.0 million in 2025.
  • Business Quant data shows Current Leases for KNSA at $3.0 million in Q4 2025, $2.7 million in Q3 2025, and $2.5 million in Q2 2025.